At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Market Closed 02-20 16:00:00 EST
3.42
-0.30
-8.06%
盘后3.43
+0.01+0.29%
19:59 EST
High3.70Low3.38Vol18.92M
Open3.64D1 Closing3.72Amplitude8.60%
Mkt Cap1.78BTradable Cap1.42BTotal Shares519.84M
T/O66.08MT/O Rate4.56%Tradable Shares415.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street
Dow Jones  ·  02-20 19:30
Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street
Recursion Pharmaceuticals CFO Ben R Taylor Disposes of Common Shares
Reuters  ·  02-20
Recursion Pharmaceuticals CFO Ben R Taylor Disposes of Common Shares
Cathie Wood’s ARK Investment buys 1.2M shares of Recursion Pharmaceuticals today
TIPRANKS  ·  02-19
Cathie Wood’s ARK Investment buys 1.2M shares of Recursion Pharmaceuticals today
BUZZ-Applied Digital, WeRide shares fall after Nvidia dissolves stake
Reuters  ·  02-19
BUZZ-Applied Digital, WeRide shares fall after Nvidia dissolves stake
Shares of Recursion Pharmaceuticals Down 6% After Nvidia Dissolves Share Stake in Co
THOMSON REUTERS  ·  02-18
Shares of Recursion Pharmaceuticals Down 6% After Nvidia Dissolves Share Stake in Co
Recursion Pharmaceuticals Shares Plunge Over 13% Premarket Following Nvidia's Complete Divestment
Stock News  ·  02-18
Recursion Pharmaceuticals Shares Plunge Over 13% Premarket Following Nvidia's Complete Divestment
Recursion Pharmaceuticals Inc. published an update to their financial calendar
Reuters  ·  02-18
Recursion Pharmaceuticals Inc. published an update to their financial calendar
Press Release: Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
Dow Jones  ·  02-18
Press Release: Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. -- Barrons.com
Dow Jones  ·  02-18
Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. -- Barrons.com
Premarket Movers | New York Times Jumps 3%; Synopsys up 4%; RXRX Slides 13%; Palo Alto Networks Plunges 8%; APLD Sinks 7%; SanDisk down 2%
Tiger Newspress  ·  02-18
Premarket Movers | New York Times Jumps 3%; Synopsys up 4%; RXRX Slides 13%; Palo Alto Networks Plunges 8%; APLD Sinks 7%; SanDisk down 2%
Synopsys Jumps over 2% While APLD Plunges 9%. Nvidia Reports Share Stake In Intel, Nokia, Synopsys; Dissolves In ARM, APLD
Reuters  ·  02-18
Synopsys Jumps over 2% While APLD Plunges 9%. Nvidia Reports Share Stake In Intel, Nokia, Synopsys; Dissolves In ARM, APLD
Novo Holdings Dissolves Share Stake In Recursion Pharmaceuticals
Reuters  ·  02-18
Novo Holdings Dissolves Share Stake In Recursion Pharmaceuticals
BRIEF-Recursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Reuters  ·  02-12
BRIEF-Recursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Recursion Pharmaceuticals Grants Inducement RSUs to 17 New Employees
Reuters  ·  02-12
Recursion Pharmaceuticals Grants Inducement RSUs to 17 New Employees
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
GlobeNewswire  ·  02-12
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
11 Stocks That Have Cratered and Look Like Buys -- Barrons.com
Dow Jones  ·  02-10
11 Stocks That Have Cratered and Look Like Buys -- Barrons.com
Nvidia Concept Stocks Rally. Applied Digital And CoreWeave Up 7%; Nebius Up 6%; Nvidia And Core Scientific Up 3%; WeRide Up 2%
Tiger Newspress  ·  02-09
Nvidia Concept Stocks Rally. Applied Digital And CoreWeave Up 7%; Nebius Up 6%; Nvidia And Core Scientific Up 3%; WeRide Up 2%
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook
Simply Wall St.  ·  02-09
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook
Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares
Reuters  ·  02-07
Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors
TIPRANKS  ·  02-07
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--